

Supplementary Material

Table S1. Virological outcomes. Patients with PCR negative for SARS-CoV-2 in nasal and oropharyngeal swabs over time from baseline in treatment group and in control group by number of PCR performed.

PCR number	Time (days), median (min-max)	HCQ group	Control group	Difference, % (95% CI)	p-value
2	7 (5 – 9)	21 (25.6)	7 (14.3)	11.3 (-2.3 – 24.9)	0.126
3	10 (7 – 16)	37 (43.5)	18 (36,0)	7.5 (-9.4 – 24.5)	0.390
4	15 (12 – 19)	52 (61.2)	24 (47.1)	14.1 (-3.1 – 31.3)	0.108
5	22 (19 – 27)	68 (80.0)	37 (71.2)	8.8 (-6.1 – 23.8)	0.235
6	28 (25 – 32)	78 (91.7)	49 (94.2)	-2.5 (-11.1 – 6.2)	0.590

Data are n (%) unless stated otherwise.

Supplementary Material - 2

Table S2. Virological outcomes. Patients with high-moderate viral load for SARS-CoV-2 (N1 Ct value < 35) in nasal and oropharyngeal swabs over time from baseline in treatment group or control group by number of PCR performed.

PCR number	Time (days), median (min-max)	HCQ group	Control group	Difference, % (95% CI)	p-value
1	-2 (-4 – -1)	62 (81.6)	41 (80.4)	1.2 (-12.8 – 15.1)	0.867
2	7 (5 – 9)	24 (30.4)	10 (23.3)	7.1 (-9.1 – 23.3)	0.402
3	10 (7 – 16)	8 (9.9)	9 (19.2)	-9.3 (-22.3 – 3.7)	0.136
4	15 (12 – 19)	3 (3.6)	4 (7.8)	-4.2 (-12.6 – 4.2%)	0.428
5	22 (19 – 26)	0	3 (6.0)	-6.0 (-12.6 – 5.8%)	0.054
6	29 (25 – 32)	0	0	-	-

Data are n (%) unless stated otherwise.

Supplementary Material-3

Table S3. Virological outcomes. Kaplan-Meier probability of negative conversion of SARS-CoV-2 PCR for each specific day.

Day	HCQ group	Control group	Difference, % (95% CI)	p-value
7	16.1 (9.9 – 25.7)	10.9 (5.1 – 22.7)	5.2 (-6.1 – 16.5)	0.392
10	33.3 (24.5 – 44.3)	21.8 (13.0 – 35.2)	11.5 (-3.2 – 26.3)	0.147
14	48.8 (38.8 – 59.8)	40.4 (28.8 – 54.7)	8.4 (-8.4 – 25.2)	0.337
21	66.7 (56.6 – 76.4)	48.0 (35.7 – 62.0)	18.7 (2.0 – 35.4)	0.034
28	86.0 (77.7 – 92.5)	85.8 (74.9 – 93.7)	0.2 (-12.0 – 12.4)	0.976

Data are % (95% CI).